Skip to main content

Table 1 Summary of the meta-analysis of the DRD2 rs1076560 in association with SUD in different populations

From: The frequency of DRD2 rs1076560 and OPRM1 rs1799971 in substance use disorder patients from the United Arab Emirates

Population Substance Phenotype Number Allele’s frequency (%) p OR (95% CI) References
C A
Caucasians Alcohol Case 171 79.00 21.00 0.14 1.34 (0.90–1.98) [30]
Control 160 83.00 17.00
African Americans Opioid Case 278 88.00 12.00 0.03 1.43 (1.04–1.97) [9]
Control 750 91.00 9.00
European Americans Case 999 83.00 17.00 0.02 1.27 (1.04–1.54)  
Control 656 86.00 14.00
African Americans Cocaine Case 45 94.00 6.00 0.53 0.66 (0.18–2.40) [27]
Control 31 92.00 8.00
Caucasians Case 74 76.00 24.00 0.003 2.74 (1.38–5.45)
Control 63 90.00 10.00
Japanese Alcohol Case 297 59.90 40.10 0.03 1.30 (1.02–1.66) [29]
Control 425 66.00 34.00
Jordanian Arabs Poly-substance Case 220 84.30 15.70 0.03 1.53 (0.90–2.68) [30]
Control 240 89.20 10.80
UAE Cohort Mixeda Case 250 88.20 11.80 0.52** 0.88 (0.61–1.28) This study
Control 262 86.80 13.20
  1. CI confidence intervals, OR odds ratio
  2. ** p value of Armitage test using the status of mixed opioids (n = 250) versus no addiction (n = 262)
  3. aMixed: include single substance and poly-substance users